-
公开(公告)号：US20210238249A1
公开(公告)日：2021-08-05
申请号：US17049301
申请日：2019-04-25
发明人： Kyuboem HAN , Chun-Hyung KIM , Yu Jin KIM , Shin-Hye YU , Nayoung KIM , Mi Jin KIM , Yong-Soo CHOI , Seo Eun LEE
IPC分类号： C07K14/705 , A61P35/00 , C07K14/47 , C12N9/64 , C12N9/16 , C07K16/32 , C07K16/28 , A61P35/04
摘要： Mitochondria modified by a targeting protein, according to one embodiment of the present invention, can be effectively delivered to a target. In addition, when a protein of interest bound to the modified mitochondria is delivered into a cell, various activities can be exhibited. The modified mitochondria can effectively cause cancer tissue death, and thus can also be used as an anticancer agent. Furthermore, various activities are exhibited according to a protein of interest loaded on modified mitochondria, and thus the modified mitochondria can be applied in the treatment of various diseases. Additionally, a fusion protein comprising a protein of interest and a fusion protein comprising a targeting protein, according to one embodiment of the present invention, can be used in order to modify mitochondria. Moreover, mitochondria modified with the fusion proteins exhibits various effects in a target cell.
-
公开(公告)号：US20230340414A1
公开(公告)日：2023-10-26
申请号：US18044560
申请日：2021-06-25
发明人： Young-cheol KANG , Kyuboem HAN , Jong-Cheon HA
CPC分类号： C12N5/0644 , A01N1/0284 , C12N2509/10
摘要： Provided are a method for obtaining active mitochondria by freezing platelets and a use of isolated mitochondria, and more specifically, to a method for obtaining mitochondria by thawing platelets after freezing the same and a pharmaceutical composition containing the mitochondria obtained by the method as an active ingredient. The present disclosure, by providing a method for obtaining mitochondria by thawing platelets in a frozen state in a preservation solution, not only enables to obtain mitochondria in which the activity is stably maintained, but also enables to provide a commercial value for donor platelets that are discarded after refrigeration for a short period of time. Additionally, the pharmaceutical composition containing platelet-derived mitochondria obtained by the above method may be effectively used to treat various diseases caused by mitochondrial dysfunction.
-
公开(公告)号：US20230270780A1
公开(公告)日：2023-08-31
申请号：US18044559
申请日：2021-08-10
发明人： Young-Cheol KANG , Kyuboem HAN , Sang-Min LIM , Hahnsun JUNG , Hye Jeong HWANG , Junyoung SON
CPC分类号： A61K35/12 , A61K9/0019 , A61K9/08 , A61K47/183 , A61K47/26
摘要： Provided is a composition for injection containing isolated mitochondria. More specifically, provided is a liquid composition for injection containing glycine, saccharide, buffer, and mitochondria, and a pharmaceutical composition comprising the liquid composition for injection as an active ingredient. The liquid composition for injection according to the present disclosure is capable of securing the safety of a mitochondrial therapeutic and maintaining the activity of mitochondria, by enhancing the stability of mitochondria for prevention or treatment of mitochondria-related diseases and preventing and inhibiting formation of blood clots in the blood of a subject who is administered with the same. Accordingly, the pharmaceutical composition according to the present disclosure may solve the aggregation that may occur when mitochondria are administered in the body and thus enables to safely and effectively inject mitochondria into the body to be used for the purpose of preventing and treating various diseases caused by mitochondrial dysfunction.
-
公开(公告)号：US20230015532A1
公开(公告)日：2023-01-19
申请号：US17780936
申请日：2020-12-11
发明人： Chun-Hyung KIM , Shin-Hye YU , Seo-Eun LEE , Jonghyeok PARK , Sunyeou KIM , Amna PARVEEN , Kyuboem HAN
IPC分类号： A61K31/409 , A23L33/10 , A61P11/00
摘要： The present invention relates to a pharmaceutical composition for preventing or treating fibrosis, containing a pheophorbide compound as an active ingredient. The pharmaceutical composition can effectively inhibit fibrosis of tissues by inhibiting signaling of TGF-β which causes fibrosis and inhibiting activation and expression of collagen and fibronectin, and is significantly superior in the anti-fibrotic activity compared to nintedanib or pirfenidone, which are commercially available therapeutic agents for pulmonary fibrosis, and therefore may be widely used in the prevention or treatment of fibrosis.
-
公开(公告)号：US20220000930A1
公开(公告)日：2022-01-06
申请号：US17483193
申请日：2021-09-23
发明人： Kyuboem HAN , Youngjun LEE
IPC分类号： A61K35/17 , A61P35/02 , A61P35/00 , A61K35/15 , C12N5/078 , C12N5/0783 , A61K9/19 , A61K9/08
摘要： An NK cells and PBMC, both having increased cytotoxicity are provided. Particularly, NK cells and PBMC which have exogenous mitochondria introduced thereinto potentiate the immune system of the human body to enhance a therapeutic effect on infectious diseases or cancer. Therefore, the NK cells and PBMC can be used in a composition for prevention or treatment of infectious diseases and cancer. Specially, autogenous NK cells and PBMC guarantee stability without the incurrence of an immune reaction, and thus would be expected to have high commercial activity.
-
6.发明公开公开(公告)号：US20240341299A1
公开(公告)日：2024-10-17
申请号：US18580458
申请日：2022-07-22
发明人： Young-Cheol KANG , Kyuboem HAN , Chun-Hyung KIM , Hong Kyu LEE , Soomin KIM , Hendra TANOTO , Yin Hua ZHANG , Zhi Jun LIN , Hui Xing CUI
IPC分类号： A01N1/02
CPC分类号： A01N1/021 , A01N1/0284
摘要： The present invention relates to a preservation solution composition for the preservation of an isolated cell, tissue, or organ, comprising isolated mitochondria; and a method for preserving an isolated cell, tissue, or organ by using the same. The preservation solution composition according to the present invention has excellent long-term preservability while maintaining the activity of isolated cell, tissue, or organ. Therefore, the present invention may be effectively used in the transplantation medicine field for ultimately improving transplant success rates and in the regenerative medicine field and the like.
-
7.发明公开公开(公告)号：US20230405052A1
公开(公告)日：2023-12-21
申请号：US18251869
申请日：2021-11-05
发明人： Chun-Hyung Kim , Kyuboem Han , Shin-Hye Yu , Yu Jin Kim , Seo-Eun Lee , Jong Hyeok Park , Gayoung Cho
摘要： The present invention relates to a pharmaceutical composition for preventing or treating fibrosis and, more specifically, to a pharmaceutical composition for preventing or treating fibrosis, comprising mitochondria as an active ingredient. When the pharmaceutical composition of the present invention comprising exogenous mitochondria as an active ingredient is administered to a subject suffering from fibrosis such as pulmonary fibrosis, hepatic fibrosis and renal fibrosis, the fibrosis of tissues may be inhibited. In addition, the pharmaceutical composition of the present invention effectively inhibits the expression of fibronectin, CTGF2, α-SMA, collagen 1A and the like during treatment of TGF-β. Therefore, the pharmaceutical composition according to the present invention may be effectively used in the prevention or treatment of fibrosis.
-
公开(公告)号：US20220211762A1
公开(公告)日：2022-07-07
申请号：US17607389
申请日：2020-04-27
发明人： Kyuboem HAN , Chun-Hyung KIM , Shin-Hye YU , Seo-Eun LEE , Sang-Min LIM , Hahnsun JUNG , Kwangmin NA , Yoon Mi HAN , Jun Young SON , Jong-Cheon HA , Kyunghee JUNG , Young-Cheol KANG , Eun-Seo LEE , Mi Jin KIM , Yong-Soo CHOI , Jung Uk HWANG , Min Ji LEE , Kyuseok KIM , Tae Nyoung CHUNG
摘要： The present invention relates to a pharmaceutical composition for the treatment of sepsis or systemic inflammatory response syndrome (SIRS) comprising mitochondria as effective ingredient. When activated macrophages and monocytes are treated with mitochondria which are effective ingredient of the pharmaceutical composition of the present invention, expression of IL-1β, TNF-α and IL-6 which are pro-inflammatory cytokines can be restored to normal levels. Furthermore, when the pharmaceutical composition of the present invention is administered to a subject suffering from sepsis, the survival rate of the subject can be remarkably increased. Therefore, the pharmaceutical composition according to the present invention can be useful for the treatment of sepsis.
-
公开(公告)号：US20210052659A1
公开(公告)日：2021-02-25
申请号：US16964476
申请日：2019-02-07
发明人： Yong-Soo CHOI , Jung Uk HWANG , Kyuboem HAN , Chun-Hyung KIM
摘要： The present invention relates to a pharmaceutical composition for prevention or treatment of rheumatoid arthritis and, more particularly, to a pharmaceutical composition comprising mitochondria as an effective ingredient for prevention or treatment of rheumatoid arthritis. When a foreign mitochondria pharmaceutical composition of the present invention is administered to a subject suffering from rheumatoid arthritis, the subject may alleviate edema and rubefaction symptoms. In addition, the pharmaceutical composition of the present invention reduces an expression level of the inflammatory cytokine IL-6, but increases an expression level of the anti-inflammatory cytokine IL-10 in the subject. Therefore, the pharmaceutical composition according to the present invention can be effectively used for preventing or treating rheumatoid arthritis.
-
公开(公告)号：US20200009198A1
公开(公告)日：2020-01-09
申请号：US16464928
申请日：2017-11-28
发明人： Yong-Soo CHOI , Chang-koo YUN , Mi-Jin KIM , Jung Uk HWANG
摘要： The present invention relates to a pharmaceutical composition containing mitochondria and, more specifically, to a pharmaceutical composition for preventing or treating muscle diseases or ischemic diseases, containing mitochondria as active ingredients. The pharmaceutical composition of the present invention contains heterologous mitochondria or cells comprising heterologous mitochondria, thereby enabling the mitochondrial activity of cells to which the same is administered to improve. Therefore, the pharmaceutical composition according to the present invention can be useful in the fundamental prevention or treatment of muscle diseases or ischemic diseases, which occur in relationship with the deterioration of mitochondrial function.
-
-
-
-
-
-
-
-
-
搜索结果
17 条记录 (耗时 0.017 秒)
